 | • レポートコード：MRC2312MG14835 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、71ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の組換え抗血友病グロブリン市場規模と予測を収録しています。・世界の組換え抗血友病グロブリン市場：売上、2018年-2023年、2024年-2029年 ・世界の組換え抗血友病グロブリン市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の組換え抗血友病グロブリン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイコック」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 組換え抗血友病グロブリンのグローバル主要企業は、Shire (Baxter)、 Bayer Healthcare、 CSL、 Pfizer、 Grifols、 Biogen、 Octapharma、 Novo Nordisk、 Greencross、 Kedrion、 BPL、 Hualan Bio、 RAAS、 Baxaltaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、組換え抗血友病グロブリンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の組換え抗血友病グロブリン市場：タイプ別、2018年-2023年、2024年-2029年 世界の組換え抗血友病グロブリン市場：タイプ別市場シェア、2022年 ・バイコック、アフスティラ、アルトゥヴィイオ 世界の組換え抗血友病グロブリン市場：用途別、2018年-2023年、2024年-2029年 世界の組換え抗血友病グロブリン市場：用途別市場シェア、2022年 ・臨床治療、医薬品研究、その他 世界の組換え抗血友病グロブリン市場：地域・国別、2018年-2023年、2024年-2029年 世界の組換え抗血友病グロブリン市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における組換え抗血友病グロブリンのグローバル売上、2018年-2023年 ・主要企業における組換え抗血友病グロブリンのグローバル売上シェア、2022年 ・主要企業における組換え抗血友病グロブリンのグローバル販売量、2018年-2023年 ・主要企業における組換え抗血友病グロブリンのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Shire (Baxter)、 Bayer Healthcare、 CSL、 Pfizer、 Grifols、 Biogen、 Octapharma、 Novo Nordisk、 Greencross、 Kedrion、 BPL、 Hualan Bio、 RAAS、 Baxalta ************************************************************* ・調査・分析レポートの概要 組換え抗血友病グロブリン市場の定義 市場セグメント 世界の組換え抗血友病グロブリン市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の組換え抗血友病グロブリン市場規模 世界の組換え抗血友病グロブリン市場規模：2022年 VS 2029年 世界の組換え抗血友病グロブリン市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの組換え抗血友病グロブリンの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の組換え抗血友病グロブリン製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：バイコック、アフスティラ、アルトゥヴィイオ 組換え抗血友病グロブリンのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：臨床治療、医薬品研究、その他 組換え抗血友病グロブリンの用途別グローバル売上・予測 ・地域別市場分析 地域別組換え抗血友病グロブリン市場規模 2022年と2029年 地域別組換え抗血友病グロブリン売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Shire (Baxter)、 Bayer Healthcare、 CSL、 Pfizer、 Grifols、 Biogen、 Octapharma、 Novo Nordisk、 Greencross、 Kedrion、 BPL、 Hualan Bio、 RAAS、 Baxalta ... |
This research report provides a comprehensive analysis of the Recombinant Antihemophilic Globulin market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Recombinant Antihemophilic Globulin market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Recombinant Antihemophilic Globulin, challenges faced by the industry, and potential opportunities for market players.
The global Recombinant Antihemophilic Globulin market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Recombinant Antihemophilic Globulin market presents opportunities for various stakeholders, including Clinical Treatment, Drug Research. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Recombinant Antihemophilic Globulin market. Additionally, the growing consumer demand present avenues for market expansion.
The global Recombinant Antihemophilic Globulin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following steps: gene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.
Key Features:
The research report on the Recombinant Antihemophilic Globulin market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Recombinant Antihemophilic Globulin market.
Market Overview: The report provides a comprehensive overview of the Recombinant Antihemophilic Globulin market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Baikoc, Afstyla), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Recombinant Antihemophilic Globulin market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Recombinant Antihemophilic Globulin market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Recombinant Antihemophilic Globulin market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Recombinant Antihemophilic Globulin market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Recombinant Antihemophilic Globulin market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Recombinant Antihemophilic Globulin market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Recombinant Antihemophilic Globulin, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Recombinant Antihemophilic Globulin market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Recombinant Antihemophilic Globulin market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Baikoc
Afstyla
Altuviiio
Market segment by Application
Clinical Treatment
Drug Research
Others
Global Recombinant Antihemophilic Globulin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Shire (Baxter)
Bayer Healthcare
CSL
Pfizer
Grifols
Biogen
Octapharma
Novo Nordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Baxalta
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Antihemophilic Globulin, market overview.
Chapter 2: Global Recombinant Antihemophilic Globulin market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Antihemophilic Globulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Antihemophilic Globulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Antihemophilic Globulin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Recombinant Antihemophilic Globulin Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Antihemophilic Globulin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Antihemophilic Globulin Overall Market Size
2.1 Global Recombinant Antihemophilic Globulin Market Size: 2022 VS 2029
2.2 Global Recombinant Antihemophilic Globulin Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Recombinant Antihemophilic Globulin Sales: 2018-2029
3 Company Landscape
3.1 Top Recombinant Antihemophilic Globulin Players in Global Market
3.2 Top Global Recombinant Antihemophilic Globulin Companies Ranked by Revenue
3.3 Global Recombinant Antihemophilic Globulin Revenue by Companies
3.4 Global Recombinant Antihemophilic Globulin Sales by Companies
3.5 Global Recombinant Antihemophilic Globulin Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Recombinant Antihemophilic Globulin Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Recombinant Antihemophilic Globulin Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Antihemophilic Globulin Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Antihemophilic Globulin Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Antihemophilic Globulin Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Antihemophilic Globulin Market Size Markets, 2022 & 2029
4.1.2 Baikoc
4.1.3 Afstyla
4.1.4 Altuviiio
4.2 By Type – Global Recombinant Antihemophilic Globulin Revenue & Forecasts
4.2.1 By Type – Global Recombinant Antihemophilic Globulin Revenue, 2018-2023
4.2.2 By Type – Global Recombinant Antihemophilic Globulin Revenue, 2024-2029
4.2.3 By Type – Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
4.3 By Type – Global Recombinant Antihemophilic Globulin Sales & Forecasts
4.3.1 By Type – Global Recombinant Antihemophilic Globulin Sales, 2018-2023
4.3.2 By Type – Global Recombinant Antihemophilic Globulin Sales, 2024-2029
4.3.3 By Type – Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
4.4 By Type – Global Recombinant Antihemophilic Globulin Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Recombinant Antihemophilic Globulin Market Size, 2022 & 2029
5.1.2 Clinical Treatment
5.1.3 Drug Research
5.1.4 Others
5.2 By Application – Global Recombinant Antihemophilic Globulin Revenue & Forecasts
5.2.1 By Application – Global Recombinant Antihemophilic Globulin Revenue, 2018-2023
5.2.2 By Application – Global Recombinant Antihemophilic Globulin Revenue, 2024-2029
5.2.3 By Application – Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
5.3 By Application – Global Recombinant Antihemophilic Globulin Sales & Forecasts
5.3.1 By Application – Global Recombinant Antihemophilic Globulin Sales, 2018-2023
5.3.2 By Application – Global Recombinant Antihemophilic Globulin Sales, 2024-2029
5.3.3 By Application – Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
5.4 By Application – Global Recombinant Antihemophilic Globulin Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Recombinant Antihemophilic Globulin Market Size, 2022 & 2029
6.2 By Region – Global Recombinant Antihemophilic Globulin Revenue & Forecasts
6.2.1 By Region – Global Recombinant Antihemophilic Globulin Revenue, 2018-2023
6.2.2 By Region – Global Recombinant Antihemophilic Globulin Revenue, 2024-2029
6.2.3 By Region – Global Recombinant Antihemophilic Globulin Revenue Market Share, 2018-2029
6.3 By Region – Global Recombinant Antihemophilic Globulin Sales & Forecasts
6.3.1 By Region – Global Recombinant Antihemophilic Globulin Sales, 2018-2023
6.3.2 By Region – Global Recombinant Antihemophilic Globulin Sales, 2024-2029
6.3.3 By Region – Global Recombinant Antihemophilic Globulin Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.4.2 By Country – North America Recombinant Antihemophilic Globulin Sales, 2018-2029
6.4.3 US Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.4.4 Canada Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.4.5 Mexico Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.5.2 By Country – Europe Recombinant Antihemophilic Globulin Sales, 2018-2029
6.5.3 Germany Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.4 France Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.5 U.K. Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.6 Italy Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.7 Russia Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.8 Nordic Countries Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.5.9 Benelux Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.6.2 By Region – Asia Recombinant Antihemophilic Globulin Sales, 2018-2029
6.6.3 China Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.4 Japan Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.5 South Korea Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.6 Southeast Asia Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.6.7 India Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.7.2 By Country – South America Recombinant Antihemophilic Globulin Sales, 2018-2029
6.7.3 Brazil Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.7.4 Argentina Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Antihemophilic Globulin Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Recombinant Antihemophilic Globulin Sales, 2018-2029
6.8.3 Turkey Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8.4 Israel Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8.5 Saudi Arabia Recombinant Antihemophilic Globulin Market Size, 2018-2029
6.8.6 UAE Recombinant Antihemophilic Globulin Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Shire (Baxter)
7.1.1 Shire (Baxter) Company Summary
7.1.2 Shire (Baxter) Business Overview
7.1.3 Shire (Baxter) Recombinant Antihemophilic Globulin Major Product Offerings
7.1.4 Shire (Baxter) Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.1.5 Shire (Baxter) Key News & Latest Developments
7.2 Bayer Healthcare
7.2.1 Bayer Healthcare Company Summary
7.2.2 Bayer Healthcare Business Overview
7.2.3 Bayer Healthcare Recombinant Antihemophilic Globulin Major Product Offerings
7.2.4 Bayer Healthcare Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.2.5 Bayer Healthcare Key News & Latest Developments
7.3 CSL
7.3.1 CSL Company Summary
7.3.2 CSL Business Overview
7.3.3 CSL Recombinant Antihemophilic Globulin Major Product Offerings
7.3.4 CSL Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.3.5 CSL Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Recombinant Antihemophilic Globulin Major Product Offerings
7.4.4 Pfizer Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Grifols
7.5.1 Grifols Company Summary
7.5.2 Grifols Business Overview
7.5.3 Grifols Recombinant Antihemophilic Globulin Major Product Offerings
7.5.4 Grifols Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.5.5 Grifols Key News & Latest Developments
7.6 Biogen
7.6.1 Biogen Company Summary
7.6.2 Biogen Business Overview
7.6.3 Biogen Recombinant Antihemophilic Globulin Major Product Offerings
7.6.4 Biogen Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.6.5 Biogen Key News & Latest Developments
7.7 Octapharma
7.7.1 Octapharma Company Summary
7.7.2 Octapharma Business Overview
7.7.3 Octapharma Recombinant Antihemophilic Globulin Major Product Offerings
7.7.4 Octapharma Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.7.5 Octapharma Key News & Latest Developments
7.8 Novo Nordisk
7.8.1 Novo Nordisk Company Summary
7.8.2 Novo Nordisk Business Overview
7.8.3 Novo Nordisk Recombinant Antihemophilic Globulin Major Product Offerings
7.8.4 Novo Nordisk Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.8.5 Novo Nordisk Key News & Latest Developments
7.9 Greencross
7.9.1 Greencross Company Summary
7.9.2 Greencross Business Overview
7.9.3 Greencross Recombinant Antihemophilic Globulin Major Product Offerings
7.9.4 Greencross Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.9.5 Greencross Key News & Latest Developments
7.10 Kedrion
7.10.1 Kedrion Company Summary
7.10.2 Kedrion Business Overview
7.10.3 Kedrion Recombinant Antihemophilic Globulin Major Product Offerings
7.10.4 Kedrion Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.10.5 Kedrion Key News & Latest Developments
7.11 BPL
7.11.1 BPL Company Summary
7.11.2 BPL Business Overview
7.11.3 BPL Recombinant Antihemophilic Globulin Major Product Offerings
7.11.4 BPL Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.11.5 BPL Key News & Latest Developments
7.12 Hualan Bio
7.12.1 Hualan Bio Company Summary
7.12.2 Hualan Bio Business Overview
7.12.3 Hualan Bio Recombinant Antihemophilic Globulin Major Product Offerings
7.12.4 Hualan Bio Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.12.5 Hualan Bio Key News & Latest Developments
7.13 RAAS
7.13.1 RAAS Company Summary
7.13.2 RAAS Business Overview
7.13.3 RAAS Recombinant Antihemophilic Globulin Major Product Offerings
7.13.4 RAAS Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.13.5 RAAS Key News & Latest Developments
7.14 Baxalta
7.14.1 Baxalta Company Summary
7.14.2 Baxalta Business Overview
7.14.3 Baxalta Recombinant Antihemophilic Globulin Major Product Offerings
7.14.4 Baxalta Recombinant Antihemophilic Globulin Sales and Revenue in Global (2018-2023)
7.14.5 Baxalta Key News & Latest Developments
8 Global Recombinant Antihemophilic Globulin Production Capacity, Analysis
8.1 Global Recombinant Antihemophilic Globulin Production Capacity, 2018-2029
8.2 Recombinant Antihemophilic Globulin Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Antihemophilic Globulin Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Antihemophilic Globulin Supply Chain Analysis
10.1 Recombinant Antihemophilic Globulin Industry Value Chain
10.2 Recombinant Antihemophilic Globulin Upstream Market
10.3 Recombinant Antihemophilic Globulin Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Antihemophilic Globulin Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer